ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.23%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$597M
AUM Growth
+$597M
(+20%)
Cap. Flow
+$37.8M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
54.95%
Holding
336
New
84
Increased
76
Reduced
73
Closed
71
Top Buys
| 1 |
Immunovant
IMVT
|
$18.7M |
| 2 |
Ascendis Pharma
ASND
|
$16.4M |
| 3 |
Zura Bio
ZURA
|
$15.3M |
| 4 |
Zai Lab
ZLAB
|
$12.3M |
| 5 |
AAM
AA Mission Acquisition Corp.
AAM
|
$10.1M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$28M |
| 2 |
Roivant Sciences
ROIV
|
$13M |
| 3 |
Edgewise Therapeutics
EWTX
|
$11.2M |
| 4 |
Merck
MRK
|
$8.47M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$6.96M |
Sector Composition
| 1 | Healthcare | 88.63% |
| 2 | Financials | 3.75% |
| 3 | Communication Services | 0.59% |
| 4 | Utilities | 0.21% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Corteva
CTVA
$49.2B
| – | – |
-11,400
| Closed | -$615K |
|
327
Cogent Communications
CCOI
$1.78B
| – | – |
-4,000
| Closed | -$226K |
|
328
Perspective Therapeutics
CATX
$251M
| – | – |
-69,985
| Closed | -$698K |
|
|
BLUE
329
DELISTED
bluebird bio
BLUE
| – | – |
-6,000
| Closed | -$5.91K |
|
330
Actinium Pharmaceuticals
ATNM
$53.3M
| – | – |
-75,133
| Closed | -$556K |
|
331
Arcutis Biotherapeutics
ARQT
$1.91B
| – | – |
-1,555
| Closed | -$14.5K |
|
332
AngioDynamics
ANGO
$432M
| – | – |
-143,862
| Closed | -$870K |
|
333
Amphastar Pharmaceuticals
AMPH
$1.37B
| – | – |
-700
| Closed | -$28K |
|
334
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
-1,850
| Closed | -$450K |
|
335
Adverum Biotechnologies
ADVM
$68.2M
| – | – |
-11,300
| Closed | -$77.5K |
|
336
Abbott
ABT
$230B
| – | – |
-3,300
| Closed | -$343K |
|